423 related articles for article (PubMed ID: 18567989)
1. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
5. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
6. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
[TBL] [Abstract][Full Text] [Related]
7. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
9. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
11. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
12. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
13. [Treatment options in non-Hodgkin lymphomas].
Tilly H
Rev Prat; 2010 Jan; 60(1):69-74. PubMed ID: 20222315
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance.
Cohen Y; Solal-Céligny P; Polliack A
Haematologica; 2003 Jul; 88(7):811-23. PubMed ID: 12857561
[TBL] [Abstract][Full Text] [Related]
15. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
Winter JN
Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal antibody therapy for malignant lymphoma].
Buske C; Dreyling M; Unterhalt M; Hiddemann W
Med Klin (Munich); 2005 Jan; 100(1):14-24. PubMed ID: 15654538
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
20. [A three-year experience with use of mabthera (rituximab) in treatment of indolent non-Hodgkin's disease refractory to standard chemotherapy].
Korolenko VO; Gershanovich ML; Tikhonova VV
Vopr Onkol; 2004; 50(4):421-5. PubMed ID: 15605764
[No Abstract] [Full Text] [Related]
[Next] [New Search]